JP2019167346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019167346A5 JP2019167346A5 JP2019087445A JP2019087445A JP2019167346A5 JP 2019167346 A5 JP2019167346 A5 JP 2019167346A5 JP 2019087445 A JP2019087445 A JP 2019087445A JP 2019087445 A JP2019087445 A JP 2019087445A JP 2019167346 A5 JP2019167346 A5 JP 2019167346A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- combination
- bacterial cell
- pharmaceutical composition
- penetrating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 36
- 210000004027 cell Anatomy 0.000 claims 32
- 230000001580 bacterial effect Effects 0.000 claims 31
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 230000000149 penetrating effect Effects 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 10
- 102000001974 Hyaluronidases Human genes 0.000 claims 10
- 229960002773 hyaluronidase Drugs 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 230000035515 penetration Effects 0.000 claims 8
- 241000607142 Salmonella Species 0.000 claims 7
- 230000000692 anti-sense effect Effects 0.000 claims 7
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 6
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 6
- 230000001506 immunosuppresive effect Effects 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 102100021723 Arginase-1 Human genes 0.000 claims 1
- 101710129000 Arginase-1 Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 1
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- -1 pGE2 Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842749P | 2013-07-03 | 2013-07-03 | |
| US61/842,749 | 2013-07-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Division JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019167346A JP2019167346A (ja) | 2019-10-03 |
| JP2019167346A5 true JP2019167346A5 (OSRAM) | 2019-12-26 |
Family
ID=52144163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Active JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
| JP2019087445A Pending JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Active JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11141492B2 (OSRAM) |
| EP (1) | EP3016716B1 (OSRAM) |
| JP (2) | JP6896420B2 (OSRAM) |
| KR (1) | KR20160027971A (OSRAM) |
| CN (1) | CN105407974A (OSRAM) |
| AU (1) | AU2014284396A1 (OSRAM) |
| BR (1) | BR112015033053A2 (OSRAM) |
| CA (1) | CA2917102A1 (OSRAM) |
| IL (1) | IL243323A0 (OSRAM) |
| WO (1) | WO2015002969A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519734D0 (en) | 2015-11-09 | 2015-12-23 | Univ Swansea | Cancer therapy |
| JP2019533149A (ja) * | 2016-09-23 | 2019-11-14 | ヴェンタナ メディカル システムズ， インク． | 腫瘍試料中の細胞外マトリックスバイオマーカーをスコアリングするための方法及びシステム |
| US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| US20220193149A1 (en) * | 2019-05-16 | 2022-06-23 | City Of Hope | Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery |
| IL292836A (en) | 2019-11-12 | 2022-07-01 | Actym Therapeutics Inc | Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products |
| AU2021324883A1 (en) | 2020-08-12 | 2023-03-23 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| CN113769063B (zh) * | 2021-09-30 | 2024-01-19 | 浙江大学 | 一种多肽ptpr在制备肿瘤免疫治疗药物中的应用 |
| KR102680316B1 (ko) * | 2021-11-01 | 2024-07-01 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
| EP4429682A2 (en) | 2021-11-09 | 2024-09-18 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖ｒｎａ仲介遺伝子抑制 |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| WO2004078140A2 (en) | 2003-03-05 | 2004-09-16 | Halozyme, Inc. | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| CN1974759B (zh) * | 2006-07-26 | 2010-06-09 | 吉林大学 | 运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用 |
| US8252755B2 (en) | 2006-09-22 | 2012-08-28 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| EP2176412B1 (en) * | 2007-06-15 | 2017-09-13 | Beth Israel Deaconess Medical Center | Bacterial mediated tnf-alpha gene silencing |
| EP2662090A1 (en) * | 2008-04-14 | 2013-11-13 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| WO2012149364A1 (en) * | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
-
2014
- 2014-07-01 EP EP14819900.3A patent/EP3016716B1/en active Active
- 2014-07-01 KR KR1020167001786A patent/KR20160027971A/ko not_active Withdrawn
- 2014-07-01 BR BR112015033053A patent/BR112015033053A2/pt not_active Application Discontinuation
- 2014-07-01 CN CN201480041314.4A patent/CN105407974A/zh active Pending
- 2014-07-01 AU AU2014284396A patent/AU2014284396A1/en not_active Abandoned
- 2014-07-01 JP JP2016524319A patent/JP6896420B2/ja active Active
- 2014-07-01 WO PCT/US2014/045086 patent/WO2015002969A1/en not_active Ceased
- 2014-07-01 CA CA2917102A patent/CA2917102A1/en not_active Abandoned
-
2015
- 2015-12-22 US US14/978,590 patent/US11141492B2/en active Active
- 2015-12-24 IL IL243323A patent/IL243323A0/en unknown
-
2019
- 2019-05-07 JP JP2019087445A patent/JP2019167346A/ja active Pending
-
2021
- 2021-09-17 US US17/478,133 patent/US20220241432A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019167346A5 (OSRAM) | ||
| JP2016530233A5 (OSRAM) | ||
| JP6731405B2 (ja) | ウイルス粒子を用いた癌免疫療法 | |
| JP2017523187A5 (OSRAM) | ||
| JP2008501728A (ja) | 癌を治療するための細菌組成物 | |
| Chen et al. | Engineered plant-derived nanovesicles facilitate tumor therapy: natural bioactivity plus drug controlled release platform | |
| Tse et al. | Current advances in BCG-unresponsive non-muscle invasive bladder cancer | |
| Shen et al. | Systemic delivery of mPEG‐masked trispecific T‐cell nanoengagers in synergy with STING agonists overcomes immunotherapy resistance in TNBC and generates a vaccination effect | |
| US20160058845A1 (en) | Administration of kynurenine depleting enzymes for tumor therapy | |
| Kubicek et al. | Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies | |
| Chen et al. | Triptolide modulates tumour-colonisation and anti-tumour effect of attenuated Salmonella encoding DNase I | |
| CN106540256A (zh) | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Lam et al. | Targeting mesenchymal stem cell therapy for severe pneumonia patients | |
| Tuthill et al. | Thymosin alpha 1: past clinical experience and future promise | |
| KRzyKawsKi | Combined bacterial and viral treatment: a novel anticancer strategy | |
| Xiao et al. | An immunometabolic patch facilitates mesenchymal stromal/stem cell therapy for myocardial infarction through a macrophage‐dependent mechanism | |
| CN107007830B (zh) | 一种无毒株弓形体和中药多糖佐剂组合物的用途、疫苗及制备方法 | |
| WO2020094865A1 (fr) | Utilisation du microrna mir-27a-5p pour traiter l'inflammation intestinale induite par clostridium difficile | |
| Pisano et al. | Updates on intravesical therapy | |
| EP0644773B1 (fr) | Complexe immunomodulateur anti-sida | |
| US20110144031A1 (en) | Pharmaceutical composition for inducing damages of endothelial cells and treating tumor and method for treating tumor by using the same | |
| Fialho et al. | Recent patents on bacterial proteins as potential anticancer agents | |
| JP2017518300A (ja) | サイトカイン−キトサンバイオコンジュゲート及びその使用方法 | |
| CN119930754A (zh) | 基于线粒体膜Atad3a-VDAC1互作的小分子肽开发在肺癌治疗中的应用 |